Idexx Laboratories · Earnings release · 8-K Exhibit 99

IDEXX Laboratories Announces Third Quarter Results

▪

Achieves third quarter revenue growth of 13% as reported and 12% organic, and T1CAG Diagnostics recurring revenue growth of 11% as

reported and 10% organic.

▪

Strong organic revenue growth was supported by IDEXX execution and commercial performance, reflecting benefits from IDEXX's innovation,

T2including over 1,700 IDEXX inVue Dx™ placements.

▪

Delivers EPS of $3.40, an increase of 21% as reported and 15% on a comparable basis, including T3operating margin expansion of 100

basis points as reported and 120 basis points on a comparable basis.

▪

Increases 2025 revenue guidance to $4,270 million - $4,300 million, an increase of $43 million or ~1% at midpoint, reflecting stronger

CAG Diagnostics recurring revenue performance and outlook for higher IDEXX inVue Dx instrument placements and revenues.

▪

Updates outlook for 2025 reported revenue growth of 9.6% - 10.3% and G1CAG Diagnostics recurring revenue reported growth of 8.3%

- 9.0%, with projected 2025 organic revenue growth of 8.8% - 9.5% and G2CAG Diagnostics recurring revenue organic growth of 7.5% - 8.2%.

▪

G3Raises 2025 EPS outlook to $12.81 - $13.01, reflecting $0.33 increase compared to prior guidance midpoint, supported by increased

revenue and operating profit margin outlooks.

WESTBROOK,

Maine, November 3, 2025— IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation,

today announced third quarter results.

Third Quarter Results

The Company reports revenues of $1,105 million for the third quarter

of 2025, an increase of 13% as reported and 12% organic, driven by Companion Animal Group ("CAG") growth of 14% as reported

and 12% organic, and Livestock, Poultry and Dairy ("LPD") revenue growth of 17% as reported and 14% organic.

Third quarter earnings per diluted share (“EPS”) were $3.40,

an increase of 21% as reported and 15% on a comparable basis. Third quarter EPS included $0.17 per share in tax benefits from share-based

compensation, $T40.09 per share of increased tax expense related to impacts of recent U.S. tax law changes, and $0.02 per share benefit

from currency changes.

IDEXX Announces Third Quarter Results

“T5IDEXX made exceptional progress on our innovation-driven growth

strategy with strong execution and global customer adoption,” said Jay Mazelsky, President and Chief Executive Officer. “Building

on the successful launch of IDEXX Cancer Dx™, new Catalyst specialty tests for Pancreatic Lipase and Cortisol, and the

transformative impact of IDEXX inVue Dx, we are delivering powerful new diagnostic capabilities. These solutions elevate clinical insights,

streamline workflows, and create meaningful value for veterinary teams. The enthusiastic response — as reflected in our strong

growth profile —highlights the trust our customers place in IDEXX."

Third Quarter Performance Highlights

Companion Animal Group (“CAG”)

CAG revenue growth was led by CAG Diagnostics recurring revenue growth

of 11% as reported and 10% organic, including 18% reported and 14% organic gains in International regions, and 8% reported and organic

growth in the U.S., outpacing sector growth levels. U.S. growth was aided by increased diagnostic frequency and an easing of clinical

visit pressures.

Additional

U.S. companion animal practice key metrics are available in the Q3 2025 Earnings Snapshot accessible on the IDEXX website, www.idexx.com/investors.

Sustained commercial execution - including net customer gains, growing

benefits from IDEXX innovation, and expansion of the premium instrument installed base - drove double-digit CAG Diagnostics recurring

revenue growth.

▪

IDEXX VetLab™ consumables generated 18% reported and 16% organic revenue growth, supported by testing utilization gains,

including increasing benefit from recent product launches, and 10% growth in IDEXX's global premium instrument installed base.

▪

Reference laboratory diagnostic and consulting services generated 10% reported and 9% organic revenue growth, with benefits

from higher testing volumes, net new customer gains, and net price benefits.

▪

T6Rapid assay products revenues declined 4% as reported and 5% on an organic basis, with volumes continuing to be impacted from

the late prior year launch of the Catalyst™ Pancreatic Lipase Test, which shifted some testing across modalities, offsetting net

price benefits.

T7CAG Diagnostics capital instrument revenues expanded 74% as reported

and 71% on an organic basis, led by very strong quarterly instrument placements, including benefits from over 1,700 IDEXX inVue Dx placements.

Veterinary software, services and diagnostic imaging systems revenues

grew 11% on a reported and organic basis for the quarter, led by cloud-native software growth and continued installed base expansion.

IDEXX Announces Third Quarter Results

Water

Water revenues grew 8% as reported and 7% organic for the quarter,

reflecting solid organic growth both in the U.S. and Internationally.

Livestock, Poultry and Dairy (“LPD”)

LPD revenues increased 17% as reported and 14% organic for the quarter,

led by strong growth across core product categories and major geographies.

Gross Profit and Operating Profit

Gross profits increased 15% as reported and 13% on a comparable basis.

Gross margin of 61.8% increased 70 basis points as reported and 80 basis points on a comparable basis, supported by Reference Labs productivity

initiatives and volume gains, strong growth of IDEXX VetLab consumables revenue, and benefits from net price realization helping to offset

inflationary impacts.

Operating margin was 32.1% for the quarter, higher than the prior year

period by 100 basis points as reported and by 120 basis points on a comparable basis. Operating margin results reflect a 12% operating

expense increase as reported and 10% growth on a comparable basis. Operating expense growth was driven by investments in commercial resources,

higher R&D spend related to advancing the Company's innovation agenda, and higher employee benefit and incentive costs.

2025Growth and Financial Performance Outlook

The Company is updating its full year revenue growth guidance range

to $4,270 million - $4,300 million, or reported growth of 9.6% - 10.3%, an increase of $43 million at midpoint. This reflects a positive

adjustment of ~1% at midpoint to full year estimates for reported revenue growth, reflecting strong CAG Diagnostics recurring revenue

performance and outlook for higher IDEXX inVue Dx instrument placements and revenues. The Company is increasing its outlook for organic

revenue growth to 8.8% - 9.5%, an increase of ~1% at midpoint, reflecting the operational performance benefits highlighted above.

G4The Company increased its full year reported operating margin outlook

to 31.6% - 31.8%, bringing the projected full year operating profit margin expansion to 260 - 280 basis points as reported and 80 - 100

basis points on a comparable basis. This outlook benefits from strong third quarter operating performance, while advancing strategic investment

priorities.

The Company updated its EPS outlook range to $12.81 - $13.01, incorporating

a $0.33 increase at midpoint versus prior guidance, reflecting $0.22 benefit from operational performance, $0.04 benefit from lower effective

tax rate, net of impacts related to recent U.S. tax law changes, and ~$0.07 combined benefit from updated estimates for interest expense,

average shares outstanding, and foreign exchange impacts. G5The updated EPS growth outlook is 20% - 22% as reported and 12% - 14% on a comparable

basis.

IDEXX Announces Third Quarter Results

The following table provides the Company's updated outlook for annual

key financial metrics in 2025 with a comparison to the prior outlook:

Amounts in millions except per share data and percentages

2025 Growth and Financial Performance Outlook

Updated

Prior

Revenue

-

-

Reported growth

-

-

Organic growth

-

-

CAG Diagnostics Recurring Revenue Growth

Reported growth

-

-

Organic growth

-

-

Operating Margin

-

-

G6Operating margin expansion

-

-

G7Comparable margin expansion

-

-

EPS

-

-

Reported growth

-

-

Comparable growth

-

9%

-

Other Key Metrics

G8Net interest expense

G9Share-based compensation tax benefit

G10Share-based compensation tax rate benefit

G11Effective tax rate

G12Share-based compensation EPS impact

G13Reduction in average shares outstanding

-

3%

2%

-

3%

G14Operating Cash Flow (% of Net Income)

-

-

G15Free Cash Flow (% of Net Income)

-

-

G16Capital Expenditures

IDEXX Announces Third Quarter Results

The following table outlines estimates of foreign currency exchange

rate impacts, net of foreign currency hedging transactions, and foreign currency exchange rate assumptions reflected in the above financial

performance outlook for 2025.

Estimated Foreign Currency Exchange Rate Impacts

Revenue growth rate impact

CAG Diagnostics recurring revenue growth rate impact

Operating margin growth impact

~ 0 bps

EPS impact

EPS growth impact

~1%

Go-Forward Foreign Currency Exchange Rate Assumptions

In U.S. dollars

euro

$

British pound

$

Canadian dollar

$

Australian dollar

$

Relative to the U.S. dollar

Japanese yen

¥

Chinese renminbi

¥

Brazilian real

R$

Conference Call and Webcast Information

IDEXX

Laboratories, Inc. will be hosting a conference call today at 8:30 a.m. (ET) to discuss its third quarter 2025 results and management’s

outlook. Individuals can access a live webcast of the conference call through a link on the IDEXX website, www.idexx.com/investors.

An archived edition of the webcast will be available after 1:00 p.m. (ET) via the same link and will remain available for one year.

The live call also will be accessible by telephone. To listen to the live conference call, please dial 1-800-330-6730 or 1-213-279-1575

IDEXX Announces Third Quarter Results

About IDEXX Laboratories, Inc.

IDEXX

is a global leader in pet healthcare innovation. Our diagnostic and software products and services create clarity in the complex, constantly

evolving world of veterinary medicine. We support longer, fuller lives for pets by delivering insights and solutions that help the veterinary

community around the world make confident decisions—to advance medical care, improve efficiency, and build thriving practices.

Our innovations also help ensure the safety of milk and water across the world and maintain the health and well-being of people and livestock.

IDEXX Laboratories, Inc. is a member of the S&P 500™ Index. Headquartered in Maine, IDEXX employs

approximately 11,000 people and offers solutions and products to customers in more than 175 countries and territories. For more information

about IDEXX, visit www.idexx.com.

Contact:

John Ravis, Investor Relations

investorrelations@idexx.com

IDEXX Announces Third Quarter Results

Note Regarding Forward-Looking Statements

This earnings release and the statements to be made in the accompanying

earnings conference call contain forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, including

statements about the Company’s business prospects and estimates of the Company’s financial results for future periods. Forward-looking

statements are included above under "2025 Growth and Financial Performance Outlook" and elsewhere and can be identified by the

use of words such as "expects", "may", "anticipates", "intends", "would", "will",

"plans", "believes", "estimates", "projected", "should", and similar words and expressions.

Our forward-looking statements include statements relating to our expectations regarding financial performance; revenue growth (including

instrument revenue growth in 2026) and EPS outlooks; operating and free cash flow forecast; projected impact of foreign currency exchange

rates and interest rates; projected operating margins and expenses and capital expenditures; projected tax, tax rate and EPS benefits

from share-based compensation arrangements; projected effective tax rates, reduction of average shares outstanding and net interest expense;

projected impact of recent U.S. tax law changes; projected impact of tariffs; trends and other factors impacting the pet healthcare industry,

including U.S. clinical visits; IDEXX inVue Dx analyzer placements and revenues; additions to the IDEXX Cancer Dx testing panel and timing

of the panel's international roll-out; and future commercial expansions and menu expansions (including the planned addition of Fine Needle

Aspiration to the IDEXX inVue Dx analyzer). These statements are intended to provide management's expectations or forecasts of future

events as of the date of this earnings release; are based on management's estimates, projections, beliefs, and assumptions as of the date

of this earnings release; and are not guarantees of future performance. These forward-looking statements involve known and unknown risks

and uncertainties that may cause the Company's actual results, levels of activity, performance or achievements to be materially different

from those expressed or implied by these forward-looking statements. These risks and uncertainties include, among other things, the matters

described under the headings "Business," "Risk Factors," "Legal Proceedings," "Management's Discussion

and Analysis of Financial Condition and Results of Operations" and "Quantitative and Qualitative Disclosures About Market Risk"

in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and in the corresponding sections of

the Company's Quarterly Reports on Form 10-Q for the quarters ended March 31, 2025, June 30, 2025, and September 30,

2025, as well as those described from time to time in the Company’s other filings with the U.S. Securities and Exchange Commission

available at www.sec.gov. The Company specifically disclaims any obligation to publicly update any forward-looking statement, whether

as a result of new information, future events or otherwise.

Statement Regarding Non-GAAP Financial Measures

The following defines terms and conventions and provides reconciliations

regarding certain measures used in this earnings release and/or the accompanying earnings conference call that are not required by, or

presented in accordance with, generally accepted accounting principles in the United States of America ("GAAP"), otherwise referred

to as non-GAAP financial measures. To supplement the Company’s consolidated results presented in accordance with GAAP, the Company

has disclosed non-GAAP financial measures that exclude or adjust certain items. Management believes these non-GAAP financial measures

provide useful supplemental information for its and investors’ evaluation of the Company’s business performance and liquidity

and are useful for period-over-period comparisons of the performance of the Company’s business and its liquidity and to the performance

and liquidity of our peers. While management believes that these non-GAAP financial measures are useful in evaluating the Company’s

business, this information should be considered as supplemental in nature and should not be considered in isolation or as a substitute

for the related financial information prepared in accordance with GAAP. In addition, these non-GAAP financial measures may not be the

same as similarly titled measures reported by other companies.

Constant

currency - Constant currency references are non-GAAP financial measures which exclude the impact of changes in foreign currency

exchange rates and are consistent with how management evaluates our performance and comparisons with prior and future periods. We estimate

the net impacts of currency on our revenue, gross profit, operating profit, and EPS results by restating results to the average exchange

rates or exchange rate assumptions for the comparative period, which includes adjusting for the estimated impacts of foreign currency

hedging transactions and certain impacts on our effective tax rates. These estimated currency changes impacted third quarter 2025 results

as follows: increased gross profit growth by 1.3%, decreased gross margin expansion by 10 basis points, increased operating expense growth

by 2.0%, increased operating profit growth by 0.6%, decreased operating profit margin growth by 20 basis points, and increased EPS growth

by 0.3%. Constant currency revenue growth represents the percentage change in revenue during the applicable period, as compared to the

prior year period, excluding the impact of changes in foreign currency exchange rates. See the supplementary analysis of results below

for revenue percentage change from currency for the three and nine months ended September 30, 2025 and refer to the 2025 Growth and

Financial Performance Outlook section of this earnings release for estimated foreign currency exchange rate impacts on 2025 projections

and estimates.

Growth

and organic revenue growth - All references to growth and organic growth refer to growth compared to the equivalent prior year

period unless specifically noted. Organic revenue growth is a non-GAAP financial measure that represents the percent change in revenue,

as compared to the same period for the prior year, net of the impact of changes in foreign currency exchange rates, certain business acquisitions,

and divestitures. Management believes that reporting organic revenue growth provides useful information to investors by facilitating easier

comparisons of our revenue performance with prior and future periods and to the performance of our peers. Organic revenue growth should

be considered in addition to, and not as a replacement of or a superior measure to, revenue growth reported in accordance with GAAP. See

the supplementary analysis of results below for a reconciliation of reported revenue growth to organic revenue growth for the three and

nine months ended September 30, 2025. Please refer to the constant currency note above for a summary of foreign currency exchange

rate impacts. Please refer to the 2025 Growth and Financial Performance Outlook section of this earnings release for estimated full year

2025 organic revenue growth for the Company and CAG Diagnostics recurring revenue growth. The percentage change in revenue resulting from

acquisitions represents revenues during the current year period, limited to the initial 12 months from the date of the acquisition, that

are directly attributable to business acquisitions. Revenue from acquisitions is expected to have an immaterial impact on projected full

year 2025 revenue growth and no impact on CAG Diagnostics recurring revenue growth.

IDEXX Announces Third Quarter Results

Comparable

growth metrics - Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth,

comparable operating profit growth and comparable operating margin gain (or growth) are non-GAAP financial measures and exclude the impact

of changes in foreign currency exchange rates and non-recurring or unusual items (if any). Please refer to the constant currency note

above for a summary of foreign currency exchange rate impacts. Management believes that reporting comparable gross profit growth, comparable

gross margin gain (or growth), comparable operating expense growth, comparable operating profit growth and comparable operating margin

gain (or growth) provides useful information to investors because it enables better period-over-period comparisons of the fundamental

financial results by excluding items that vary independent of performance and provides greater transparency to investors regarding key

metrics used by management. Comparable gross profit growth, comparable gross margin gain (or growth), comparable operating expense growth,

comparable operating profit growth and comparable operating margin gain (or growth) should be considered in addition to, and not as replacements

of or superior measures to, gross profit growth, gross margin gain, operating expense growth, operating profit growth and operating margin

gain reported in accordance with GAAP.

The reconciliation of these non-GAAP financial measures is as follows:

Three Months Ended

Year-over-Year

Nine Months Ended

Year-over-Year

Dollar amounts in thousands

Change

Change

Gross profit and growth (as reported)

$

$

%

$

$

%

Gross margin and margin gain

%

%

bps

%

%

bps

Less: comparability adjustments

Change from currency

—

—

Comparable gross profit and growth

$

$

%

$

$

%

Comparable gross margin and margin gain

%

%

bps

%

%

bps

Operating expenses and growth (as reported)

$

$

%

$

$

2

%

Less: comparability adjustments

Change from currency

—

—

Now-concluded litigation matter

—

—

)

Comparable operating expense and growth

$

$

%

$

$

9

%

Operating profit and growth (as reported)

$

$

%

$

$

%

Operating margin and margin gain

%

%

bps

%

%

bps

Less: comparability adjustments

Change from currency

—

—

Now-concluded litigation matter

—

—

)

Comparable operating profit and growth

$

$

%

$

$

%

Comparable operating margin and margin gain

%

%

bps

%

%

bps

Amounts presented may not recalculate due to rounding.

Projected 2025 comparable operating margin expansion outlined in the

2025 Growth and Financial Performance Outlook section of this earnings release reflects the following adjustments: (i) adjustment

to projected 2025 operating margin for an immaterial impact from year-over-year foreign currency exchange rate changes at noted exchange

rates; and (ii) adjustment to projected 2025 operating margin for positive impact of the approximately $9 million discrete litigation

expense accrual adjustment in the first quarter of 2025; and (iii) adjustment to full year 2024 reported operating margin for the

negative impact of the $61.5 million discrete litigation expense accrual adjustment in the second quarter of 2024.

IDEXX Announces Third Quarter Results

These impacts described above reconcile reported gross profit growth,

gross margin gain, operating expense growth, operating profit growth and operating margin gain (including projected 2025 operating margin

expansion) to comparable gross profit growth, comparable gross margin gain, comparable operating expense growth, comparable operating

profit growth and comparable operating margin gain for the Company.

Comparable

EPS growth - Comparable EPS growth is a non-GAAP financial measure that represents the percentage change in earnings per share

(diluted) ("EPS") for a measurement period, as compared to the prior base period, net of the impact of changes in foreign currency

exchange rates from the prior base period and excluding the tax benefits of share-based compensation activity under ASU 2016-09, Compensation-Stock

Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting, and non-recurring or unusual items (if any). Management

believes comparable EPS growth is a more useful way to measure the Company’s business performance than EPS growth because it enables

better period-over-period comparisons of the fundamental financial results by excluding items that vary independent of performance and

provides greater transparency to investors regarding a key metric used by management. Comparable EPS growth should be considered in addition

to, and not as a replacement of or a superior measure to, EPS growth reported in accordance with GAAP. Please refer to the constant currency

note above for a summary of foreign currency exchange rate impacts.

The reconciliation of this non-GAAP financial measure is as follows:

Three Months Ended

Year-over-Year

Nine Months Ended

Year-over-Year

Growth

Growth

Earnings per share (diluted) and growth

$

$

%

$

$

%

Less: comparability adjustments

Share-based compensation activity

Now-concluded litigation matter

—

—

)

Change from currency

—

—

Comparable EPS and growth

$

$

%

$

$

%

Amounts presented may not recalculate due to rounding.

Projected 2025 comparable EPS growth outlined in the 2025 Growth and

Financial Performance Outlook section of this earnings release reflects the following adjustments: (i) adjustment to projected full

year 2025 reported EPS for estimated positive share-based compensation activity of ~$0.28; and (ii) adjustment to projected full

year 2025 reported EPS for estimated positive year-over-year foreign currency exchange rate change impact of ~$0.11 at noted exchange

rates; (iii) adjustment to projected full year 2025 reported EPS for a positive $0.08 impact from the discrete litigation expense

accrual adjustment in the first quarter of 2025; (iv) adjustment to full year 2024 reported EPS for a negative $0.56 impact from

the discrete litigation expense accrual adjustment in the second quarter of 2024; and (v) adjustment to full year 2024 reported EPS

for positive impact of share-based compensation activity of $0.24.

These impacts and those described in the constant currency note above

reconcile reported EPS growth (including projected 2025 reported EPS growth) to comparable EPS growth for the Company.

Segment

and Other Income from Operations - We report segment income from operations in our Segment Information table below. Segment

income from operations is a non-GAAP financial measure that adjusts for the impact of foreign currency transaction gains and losses and

should be considered in addition to, and not as a replacement for, or superior measure to, income from operations. We exclude foreign

currency transaction gains and losses for each reportable segment (CAG, Water, and LPD) from segment income from operations and report

the full amount of foreign currency transaction gains and losses in Other. We believe that reporting segment income from operations provides

supplemental analysis to help investors further evaluate each reportable segment’s business performance by excluding foreign currency

transaction gains and losses, which are centrally managed by our corporate treasury function and which we do not consider relevant for

assessing the results of each reportable segment’s operations. In addition, we believe that reporting segment income from operations

provides information to investors regarding key metrics that are used by management, including our chief operating decision-maker, in

evaluating the performance of each reportable segment.

IDEXX Announces Third Quarter Results

The reconciliation of this non-GAAP financial measure is as follows

Amounts in thousands

Three Months Ended September 30,

Income from

Operations

Impact from

Foreign

Currency

Segment and

Other Income

from

Operations

Income from

Operations

Impact from

Foreign

Currency

Segment and

Other Income

from

Operations

CAG

$

$

$

$

$

)

$

Water

)

LPD

)

Other

)

)

Total

$

$

—

$

$

$

—

$

Amounts in thousands

Nine Months Ended September 30,

Income from

Operations

Impact from

Foreign

Currency

Segment and

Other Income

from

Operations

Income from

Operations

Impact from

Foreign

Currency

Segment and

Other Income

from

Operations

CAG

$

$

$

$

$

$

Water

LPD

)

Other

)

)

Total

$

$

—

$

$

$

—

$

Free cash

flow - Free cash flow is a non-GAAP financial measure and means, with respect to a measurement period, the cash generated from

operations during that period, reduced by the Company’s investments in property and equipment. Management believes free cash flow

is a useful measure because it indicates the cash the operations of the business are generating after appropriate reinvestment for recurring

investments in property and equipment that are required to operate the business. Free cash flow should be considered in addition to, and

not as a replacement of or a superior measure to, net cash provided by operating activities. See the supplementary analysis of results

below for our calculation of free cash flow for the three and nine months ended September 30, 2025 and 2024. To estimate projected

2025 free cash flow, we have deducted projected purchases of property and equipment (also referred to as capital expenditures) of approximately

$140 million. Free cash flow conversion, or the net income to free cash flow ratio, is a non-GAAP financial measure that is defined as

free cash flow, with respect to a measurement period, divided by net income for the same period. To calculate trailing twelve-month net

income to free cash flow ratio for the twelve months ended September 30, 2025, we have deducted purchases of property and equipment

of approximately $124 million from net cash provided from operating activities of approximately $1,088 million, divided by net income

of approximately $1,027 million.

Debt to

Adjusted EBITDA (Leverage Ratios) - Adjusted EBITDA, gross debt, and net debt are non-GAAP financial measures. Adjusted EBITDA

is a non-GAAP financial measure of earnings before interest, taxes, depreciation, amortization, non-recurring transaction expenses incurred

in connection with acquisitions, share-based compensation expense, and certain other non-cash losses and charges. Management believes

that reporting Adjusted EBITDA, gross debt, and net debt in the Debt to Adjusted EBITDA ratios provides supplemental analysis to help

investors further evaluate the Company's business performance and available borrowing capacity under the Company's credit facility.

Adjusted EBITDA, gross debt, and net debt should be considered in addition to, and not as replacements of or superior measures to, net

income or total debt reported in accordance with GAAP. For further information on how Adjusted EBITDA and the Debt to Adjusted EBITDA

Ratios are calculated, see the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report

on Form 10-Q for the quarter ended September 30, 2025.

Notes and Definitions

Discrete

litigation expense accrual - During the second quarter of 2024, the Company increased its previously

established $27.5 million accrual related to a now-concluded litigation matter by $61.5 million. During the first quarter of 2025, the

Company reduced this previously established $89.0 million accrual by approximately $9 million, resulting in a total accrual for this now-concluded

litigation matter of approximately $80 million as of March 31, 2025, which represented our best estimate at that time of the amount

of the loss.

Now-concluded

litigation matter - The Company was a defendant in a litigation matter involving an alleged breach of contract for underpayment

of royalty payments made from 2004 through 2017 under an expired patent license agreement, and the trial court ruled in favor of the plaintiff

in 2020. Following appeals and in light of the appellate court's April 3, 2025 decision, on April 17, 2025, the Company paid

the judgment of approximately $80 million, and the plaintiff executed a satisfaction and release of judgment, which was filed with the

trial court on the same date, concluding this matter. For further information, see the Company's Quarterly Report on Form 10-Q for

IDEXX Announces Third Quarter Results

IDEXX Laboratories, Inc. and Subsidiaries

Condensed Consolidated Statement of Operations

Amounts

in thousands except per share data (Unaudited)

Three Months Ended

Nine Months Ended

Revenue:

Revenue

$

$

$

$

Expenses and Income:

Cost of revenue

Gross profit

Sales and marketing

General and administrative

Research and development

Total operating expense

Income from operations

Interest expense, net

)

)

)

)

Income before provision for income taxes

Provision for income taxes

Net Income:

Net income attributable to stockholders

$

$

$

$

Earnings per share: Basic

$

$

$

$

Earnings per share: Diluted

$

$

$

$

Shares outstanding: Basic

Shares outstanding: Diluted

IDEXX Laboratories, Inc. and Subsidiaries

Selected Operating Information (Unaudited)

Three Months Ended

Nine Months Ended

Operating Ratios

Gross profit

%

%

%

%

(as a percentage of revenue):

Sales, marketing, general and administrative expense

%

%

%

%

Research and development expense

%

%

%

%

Income from operations1

%

%

%

%

1Amounts presented may not recalculate due to rounding.

IDEXX Announces Third Quarter Results

IDEXX Laboratories, Inc. and Subsidiaries

Segment and Other Information

Amounts

in thousands (Unaudited)

Three Months Ended

Percent of

Percent of

Revenue

Revenue

Revenue:

CAG

$

$

Water

LPD

Other

Total

$

$

Gross Profit:

CAG

$

%

$

%

Water

%

%

LPD

%

%

Other

%

%

Total

$

%

$

%

Income from Operations:

CAG

$

%

$

%

Water

%

%

LPD

%

%

Other

)

)%

%

Total

$

%

$

%

Nine Months Ended

Percent of

Percent of

Revenue

Revenue

Revenue:

CAG

$

$

Water

LPD

Other

Total

$

$

Gross Profit:

CAG

$

%

$

%

Water

%

%

LPD

%

%

Other

%

%

Total

$

%

$

%

Income from Operations:

CAG

$

%

$

%

Water

%

%

LPD

%

%

Other

%

%

Total

$

%

$

%

IDEXX Announces Third Quarter Results

IDEXX Laboratories, Inc. and Subsidiaries

Revenues and Revenue Growth Analysis by Product and Service Categories and by Domestic and International Markets

Amounts

in thousands (Unaudited)

Three Months Ended

Net Revenue

Dollar

Change

Reported

Revenue

Growth1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth1

CAG

$

$

$

%

%

—

%

United States

%

—

—

%

International

%

%

—

%

Water

$

$

$

%

%

—

%

United States

%

—

—

%

International

%

%

—

%

LPD

$

$

$

%

%

—

%

United States

%

—

—

%

International

%

%

—

%

Other

$

$

$

%

—

—

%

Total Company

$

$

$

%

%

—

%

United States

%

—

—

%

International

%

%

—

%

Three Months Ended

Net CAG Revenue

Dollar

Change

Reported

Revenue

Growth1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth1

CAG Diagnostics recurring revenue:

$

$

$

%

%

—

%

IDEXX VetLab consumables

%

%

—

%

Rapid assay products

)

)%

%

—

)%

Reference laboratory diagnostic and consulting services

%

%

—

%

CAG Diagnostics services and accessories

%

%

—

%

CAG Diagnostics capital – instruments

$

$

$

%

%

—

%

Veterinary software, services and diagnostic imaging systems:

$

$

$

%

%

—

%

Recurring revenue

%

%

—

%

Systems and hardware

%

)%

—

%

Net CAG revenue

$

$

$

%

%

—

%

Three Months Ended

Dollar

Change

Reported

Revenue

Growth1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth1

CAG Diagnostics recurring revenue:

$

$

$

%

%

—

%

United States

%

—

—

%

International

%

%

—

%

1See Statements Regarding Non-GAAP Financial Measures,

above. Amounts presented may not recalculate due to rounding.

IDEXX Announces Third Quarter Results

IDEXX Laboratories, Inc. and Subsidiaries

Revenues and Revenue Growth Analysis by Product and Service Categories

and by Domestic and International Markets

Amounts in thousands (Unaudited)

Nine Months Ended

Net Revenue

Dollar

Change

Reported

Revenue

Growth1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth1

CAG

$

$

$

%

%

—

%

United States

%

—

%

%

International

%

%

—

%

Water

$

$

$

%

%

—

%

United States

%

—

—

%

International

%

%

—

%

LPD

$

$

$

%

%

—

%

United States

%

—

—

%

International

%

%

—

%

Other

$

$

$

%

—

—

%

Total Company

$

$

$

%

%

—

%

United States

%

—

%

%

International

%

%

—

%

Nine Months Ended

Net CAG Revenue

Dollar

Change

Reported

Revenue

Growth1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth1

CAG Diagnostics recurring revenue:

$

$

$

%

%

—

%

IDEXX VetLab consumables

%

%

—

%

Rapid assay products

)

)%

%

—

)%

Reference laboratory diagnostic and consulting services

%

%

—

%

CAG Diagnostics services and accessories

%

%

—

%

CAG Diagnostics capital – instruments

$

$

$

%

%

—

%

Veterinary software, services and diagnostic imaging systems:

$

$

$

%

)%

%

%

Recurring revenue

%

)%

%

%

Systems and hardware

%

)%

%

%

Net CAG revenue

$

$

$

%

%

—

%

Nine Months Ended

Dollar

Change

Reported

Revenue

Growth1

Percentage

Change from

Currency

Percentage

Change from

Acquisitions

Organic

Revenue

Growth1

CAG Diagnostics recurring revenue:

$